Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Fish Oil in Major Depressive Disorder

This study has been completed.
Department of Health
Information provided by:
National Science Council, Taiwan Identifier:
First received: December 31, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted

The whole three-year study was divided into two major parts: (A) the 12-week, double-blind, randomized controlled, parallel omega-3 fatty acid monotherapy study in 60 patients with mild to moderate major depressive disorder. (B) The double-blind, randomized controlled, parallel omega-3 fatty acid add-on prevention study in 60 patients with major depressive disorder in recovery status.

The goals of this study were to examine the therapeutic and recurrence prevention effects of omega-3 fatty acids on major depressive disorder.

Condition Intervention
Major Depressive Disorder
Dietary Supplement: Omega-3 fatty acids
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Fish Oil in Major Depressive Disorder: a Double-Blind Placebo-Controlled Monotherapy Trail to Demonstrate the Therapeutic and Preventive Effects of Depression

Resource links provided by NLM:

Further study details as provided by National Science Council, Taiwan:

Primary Outcome Measures:
  • HRSD [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • BDI [ Designated as safety issue: No ]
  • Adverse effects [ Designated as safety issue: Yes ]
  • Recurrence rate [ Designated as safety issue: No ]

Enrollment: 89
Study Start Date: January 2005
Study Completion Date: December 2007
Arms Assigned Interventions
Experimental: omega-3 fatty acids Dietary Supplement: Omega-3 fatty acids
Placebo Comparator: Placebo Dietary Supplement: Placebo


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. DSM-IV criteria for major depressive disorder.
  2. Age being age 18-65.
  3. Capacity and willingness to give written informed consent.

Exclusion Criteria:

  1. Any major medical illnesses.
  2. A recent or past history of any Axis-I diagnoses besides major depressive disorder, including psychotic disorders; cognitively impaired mental disorders; impulse control disorders; substance use disorder or substance abuse (last 6 months prior to the studies); primary anxiety disorders, including post-traumatic stress disorder and panic disorder; and bipolar disorders; or Axis-II diagnoses, i.e. borderline and antisocial personality disorder.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00816322

China Medical University
Taichung, Taiwan, 404
Sponsors and Collaborators
National Science Council, Taiwan
Department of Health
  More Information

No publications provided Identifier: NCT00816322     History of Changes
Other Study ID Numbers: DMR93-IRB-87
Study First Received: December 31, 2008
Last Updated: December 31, 2008
Health Authority: Taiwan: Institutional Review Board

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mental Disorders
Mood Disorders
Pathologic Processes processed this record on November 27, 2014